南通,中国; 珠海,中国 | 全职 | Job ID: 11669
About the role:
百欧恩泰(珠海) MAH质量保证(QA)负责人是一个领导岗位,负责监管本公司及其CDMO(合同开发与生产组织)的所有质量保证活动。该负责人将确保生物制品的生产、检测、放行及分销环节均符合监管要求、行业标准以及BioNTech内部的各项政策、标准和标准操作规程(SOP)。此外,该负责人将建立和提升百欧恩泰(珠海) MAH质量管理体系(QMS)包括监管CDMO相关活动,对CDMO实施质量监督,推动持续改进举措,与跨职能团队协作,并确保产品质量与患者安全达到高标准。该岗位负责产品放行给临床试验和商业化市场
The QA Head for BioNTech-Zhuhai MAH is a leadership role responsible for the quality assurance of the drug products manufactured by BioNTech subsidiaries or CDMOs. The incumbent will ensure quality compliance with China regulatory requirements, industry standards, and BioNTech internal policies, standards, and SOPs for the manufacturing, testing, release and distribution of biological products (clinical and commercial). The incumbent will establish and improve the BioNTech MAH QMS for the assurance of drug products and oversight of the CDMO activities and drive continuous improvement initiatives, work with cross-functional teams, and ensure the highest standards of product quality and patient safety. The incumbent will be responsible for drug product release for both clinical trials and commercial markets.
Your contribution:
A good match:
BioNTech 重视每一位团队成员的福祉,为多元化的员工提供全面的福利保障。我们提供具有市场竞争力的薪酬方案,具体将根据职位、工作地点及候选人资历与经验综合确定。注:各项福利的实际适用范围、享有条件及具体内容可能因所在地而异,最终以公司内部政策及当地法律法规为准。
申请方式: 请通过我们的在线申请链接提交以下材料:
个人简历
学位证书及职业资格证书复印件
联系方式
重要提示:
我们仅接受通过链接在线提交的求职申请。
提交申请即视为您知悉,招聘流程中将依相关法律法规进行背景调查。如您进入候选名单,BioNTech 将通过合作服务机构“HireRight”开展背景调查工作,招聘专员将及时与您沟通具体安排。
我们诚挚期待您的加入。

Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases.
BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress.
BioNTech was founded in 2008 by scientists and physicians to translate science into survival by combining fundamental research and operational excellence. At BioNTech, we have been conducting fundamental research of mRNA technologies in the field of individualized cancer medicine for more than a decade. Some of our colleagues, including our co-founders, have been researching and developing mRNA-based vaccines for more than 25 years.
Ready to join us on this journey? Explore the opportunities and become part of a team that aspires to turn bold ideas into real-world solutions: https://www.biontech.com/int/en/home/careers.html
🔗 Privacy Statement: https://www.biontech.com/int/en/home/data-privacy-statement.html
🔗 Imprint: https://www.biontech.com/int/en/home/imprint.html